At the IGTP TODAY

News

The European Innovation Council provides €3 million in funding for a project with IGTP involvement

The European Commission has granted €2,999,101 in funding to the NanoBiCar project, coordinated by Universitat Politècnica de València, with the participation of the Germans Trias i Pujol Research Institute (IGTP). The grant falls within the EIC Pathfinder Program of the European Innovation Council (EIC), a highly competitive program aimed at identifying, developing, and scaling up breakthrough technologies and disruptive innovations.

- Campus Can Ruti, Research

New study finds a promising combined therapy for multiple sclerosis

Researchers from Barcelona's Germans Trias i Pujol Institute and Josep Carreras Leukaemia Research Institute have found a potential new way to improve the treatment of multiple sclerosis (MS) using a novel combined therapy. The results, published in the Journal of Clinical Investigation, builds on two harmonized Phase I clinical trials funded by the European Union, focusing on the use of Vitamin D3 tolerogenic dendritic cells (VitD3-tolDCs) to regulate the immune response in MS patients. The team is now preparing to move into Phase II trials to further explore these findings.

- Projects, Research

Keeping a longer overnight fast and eating an early breakfast may be associated with a lower body mass index

To keep weight in check, it is not only important to consider what we eat, but also the times at which we eat. According to a study published in the International Journal of Behavioral Nutrition and Physical Activity, there are two specific habits that are associated with a lower body mass index (BMI) in the long term: keeping a longer overnight fast and eating breakfast early. This research was led by ISGlobal and was carried out in collaboration with the GCAT cohort from IGTP.

- Campus Can Ruti, Research

The Research Institute of the Germans Trias i Pujol Hospital demonstrates how personalised medicine helps to control the effects of acromegaly earlier

IGTP leading the first study in the world to prove that personalised therapies are more effective than classic drugs indicated for the treatment of this rare hormonal disease. It is based on response biomarkers that, depending on what they indicate, allow the best possible treatment to be assigned earlier. In addition to very noticeable facial and skeletal deformities, acromegaly causes severe alterations in other parts of the body. Published in The Journal of Clinical Endocrinology & Metabolism.